New West Nile virus control targeted to clinical laboratories.

2003 AUG 14 - (NewsRx.com & NewsRx.net) -- Boston Biomedica, Inc., (BBI) announced the introduction of a new quality control designed to monitor quality of laboratory testing for West Nile Virus infections.

This new Quality Control Product, Accurun 165 West Nile IgM & IgG Positive control, enables hospital and clinical laboratory personnel performing diagnostic tests to efficiently check the validity of tests results that detect antibodies to West Nile Virus. Boston Biomedica also recently launched West Nile Virus Nucleic Acid Positive (Accurun 365) and Negative (Accurun 865) controls, to be used in blood banks for quality control of blood donor screening tests. …